Avgoustou Paris, Jailani Ameera B A, Desai Aditya J, Roberts David J, Lilley Ewan R, Stothard Grant W, Skerry Timothy M, Richards Gareth O
Division of Clinical Medicine, University of Sheffield, Sheffield, United Kingdom.
Front Pharmacol. 2024 Sep 23;15:1455231. doi: 10.3389/fphar.2024.1455231. eCollection 2024.
Receptor activity-modifying proteins (RAMPs) are known to modulate the pharmacology and function of several G-protein-coupled receptors (GPCRs), including the parathyroid hormone 1 receptor (PTH1R). However, the precise effects of different RAMPs on PTH1R signalling and trafficking remain poorly understood. This study investigated the impact of RAMP2 and RAMP3 on PTH1R function using a range of PTH and PTH-related protein (PTHrP)-derived ligands.
We employed FRET imaging to assess PTH1R interactions with RAMPs. Cell surface expression of PTH1R was evaluated in the presence of RAMPs. PTH1R-mediated cAMP accumulation, β-arrestin recruitment, and calcium signalling were measured in response to various ligands. Antibody-capture scintillation proximity assays were used to examine G-protein activation patterns.
PTH1R preferentially interacted with RAMP2 and, to a lesser extent, RAMP3, but not with RAMP1. RAMP3 co-expression reduced cell surface expression of PTH1R. RAMP2 significantly enhanced PTH1R-mediated signalling responses to PTH (1-34), PTHrP (1-34), PTH (1-84), and PTH (1-17) analogue ZP2307, while RAMP3 co-expression attenuated or abolished these responses. Full-length PTHrP analogues exhibited lower potency and efficacy than PTHrP (1-34) in activating PTH1R. RAMP2 increased the potency and/or efficacy of these analogues, whereas RAMP3 reduced these responses. RAMP2 differentially modulated G-protein activation by PTH1R in a ligand-dependent manner, with PTH (1-34) and PTHrP (1-34) inducing distinct patterns of G-protein subtype activation.
These findings highlight the complex role of RAMPs in regulating PTH1R signalling and trafficking, revealing differential effects of RAMP2 and RAMP3 on receptor function. The data suggest that targeting the PTH1R/RAMP2 complex may be a promising strategy for developing novel bone anabolic therapies by leveraging biased agonism and functional selectivity. Further research using physiologically relevant models is needed to elucidate the therapeutic potential of this approach.
已知受体活性修饰蛋白(RAMP)可调节多种G蛋白偶联受体(GPCR)的药理学特性和功能,包括甲状旁腺激素1型受体(PTH1R)。然而,不同RAMP对PTH1R信号传导和转运的确切影响仍知之甚少。本研究使用一系列甲状旁腺激素(PTH)和甲状旁腺激素相关蛋白(PTHrP)衍生的配体,研究了RAMP2和RAMP3对PTH1R功能的影响。
我们采用荧光共振能量转移(FRET)成像来评估PTH1R与RAMP的相互作用。在有RAMP存在的情况下评估PTH1R的细胞表面表达。测量PTH1R介导的环磷酸腺苷(cAMP)积累、β-抑制蛋白募集和钙信号传导对各种配体的反应。使用抗体捕获闪烁邻近分析来检测G蛋白激活模式。
PTH1R优先与RAMP2相互作用,在较小程度上与RAMP3相互作用,但不与RAMP1相互作用。RAMP3共表达降低了PTH1R的细胞表面表达。RAMP2显著增强了PTH1R介导的对PTH(1-34)、PTHrP(1-34)、PTH(1-84)和PTH(1-17)类似物ZP2307的信号反应,而RAMP3共表达减弱或消除了这些反应。全长PTHrP类似物在激活PTH1R方面表现出比PTHrP(1-34)更低的效力和效能。RAMP2增加了这些类似物的效力和/或效能,而RAMP3降低了这些反应。RAMP2以配体依赖性方式差异性地调节PTH1R介导的G蛋白激活,PTH(1-34)和PTHrP(1-34)诱导不同模式的G蛋白亚型激活。
这些发现突出了RAMP在调节PTH1R信号传导和转运中的复杂作用,揭示了RAMP2和RAMP3对受体功能的不同影响。数据表明,通过利用偏向激动作用和功能选择性,靶向PTH1R/RAMP2复合物可能是开发新型骨合成代谢疗法的一种有前景的策略。需要使用生理相关模型进行进一步研究,以阐明这种方法的治疗潜力。